A. Olotu, Ifakara Health Institute - Immune responses in malaria-exposed children immunised with a new generation blood-stage malaria vaccine.

科学家们发现了一种名为Pf网织红细胞结合蛋白同源物5 （PfRH5）的蛋白质，在对生活在无疟疾地区的猴子和人类进行的研究中，它作为一种候选疟疾疫苗显示出了有希望的结果。这种疫苗在疟疾流行地区的成人、幼儿和婴儿中产生保护性抗体反应的安全性和能力尚不清楚。ARL候选人将进行一项临床试验，并使用标准的实验室技术来确定这种疫苗在成人、幼儿和婴儿中是否安全且耐受性良好，并在实验室测试中发现它是否能产生能够杀死在红细胞中生长的寄生虫的抗体。这项研究将招募居住在坦桑尼亚巴加莫约疟疾低传播地区的志愿者。这项研究将提供关于将PfRH5蛋白纳入疟疾疫苗的可能性的新知识，并为进行更大规模实地试验以评估疗效的决定提供信息。结果还将确定在进行更大规模的实地试验之前是否有进一步改进这种疫苗的余地。

Scientists have discovered a protein called Pf reticulocyte-binding protein homolog 5 (PfRH5) which has shown promising results as a candidate malaria vaccine in studies conducted in monkeys and humans living in areas where there is no malaria. The safety and the ability of this vaccine to produce protective antibody responses in adults, young children and infants residing in areas with malaria is unknown. The ARL candidate will conduct a clinical trial and use standard laboratory techniques to determine if this vaccine is safe and well-tolerated in adults, young children and infants and to find out if it can produce antibodies capable of killing parasites growing in red blood cells in laboratory tests. The study will recruit volunteers residing in a low malaria transmission area in Bagamoyo, Tanzania. The study will provide new knowledge with regard to the potential for PfRH5 protein to be included in a malaria vaccine and inform decisions to conduct larger field trials to evaluate efficacy. The results will also identify whether there is scope to further improve this vaccine before conducting bigger trials in the field.